Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes (Q35839675)

scientific article published in July 2004

Language	Label	Description	Also known as
English	Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes	scientific article published in July 2004

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

10 August 2017

1 reference

Europe PubMed Central

title

Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes (English)

1 reference

stated in

Europe PubMed Central

10 August 2017

1 reference

2

William G Kaelin

1 reference

stated in

Europe PubMed Central

10 August 2017

James Brugarolas

1

1 reference

stated in

Europe PubMed Central

10 August 2017

1 July 2004

1 reference

stated in

Europe PubMed Central

10 August 2017

1 reference

Europe PubMed Central

10 August 2017

6

1 reference

stated in

Europe PubMed Central

10 August 2017

1

1 reference

stated in

Europe PubMed Central

10 August 2017

7-10

1 reference

stated in

Europe PubMed Central

10 August 2017

A serine/threonine kinase gene defective in Peutz-Jeghers syndrome

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

The AMP-activated protein kinase cascade--a unifying system for energy control

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Oncogenic alterations of metabolism

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

The phosphoinositide 3-kinase pathway

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Gleevec: prototype or outlier?

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

The LKB1 tumor suppressor negatively regulates mTOR signaling

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Akt regulates growth by directly phosphorylating Tsc2

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

How oxygen makes its presence felt

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Molecular genetic advances in tuberous sclerosis

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Cancer. Addiction to oncogenes--the Achilles heal of cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

PTEN: one gene, many syndromes

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Loss of tuberin, the tuberous-sclerosis-complex-2 gene product is associated with angiogenesis

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Hamartomatous polyposis syndromes: molecular genetics, neoplastic risk, and surveillance recommendations

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Vascular abnormalities and deregulation of VEGF in Lkb1-deficient mice

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

eIF-4E expression and its role in malignancies and metastases.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

eIF4E--from translation to transformation

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Will mTOR inhibitors make it as cancer drugs?

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

TSC2 regulates VEGF through mTOR-dependent and -independent pathways

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

LKB1 is the upstream kinase in the AMP-activated protein kinase cascade

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

TSC2 mediates cellular energy response to control cell growth and survival

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

LKB1, a protein kinase regulating cell proliferation and polarity

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Signaling control of mRNA translation in cancer pathogenesis

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Identifiers

DOI

10.1016/J.CCR.2004.06.020

1 reference

stated in

Europe PubMed Central

10 August 2017

1 reference

Europe PubMed Central

PubMed ID

15261137

retrieved

10 August 2017

ResearchGate publication ID

8448728

0 references

Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes (Q35839675)

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Navigation menu

Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes (Q35839675)

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Navigation menu

Search